Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and safety of repeat doses of fluticasone furoate + GW642444 (vilanterol) in healthy subjects and subjects with severe renal impairment
2010-020826-17Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fluticasone and vilanterol in asthma, chronic obstructive pulmonary disease (COPD) and chronic kidney disease (CKD) (2 arms), sponsored by GSK. Primary endpoints: Fluticasone furoate pharmacokinetics, GW642444 (vilanterol) pharmacokinetics and 1 more. Started Aug 2010; status: completed.
02
Drugs
fluticasonevilanterol
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2010-020826-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020826-17.